Pfizer's Ibrance clears first hurdle to early access in U.K.

Pfizer's ($PFE) new cancer standout, Ibrance, has taken its first step toward joining the U.K.'s Early Access to Medicines program, winning the "promising innovative medicine" tag from the country's Medicines and Healthcare Regulatory Agency. Since scoring a quick FDA approval last February, the breast cancer-fighter--green-lighted for patients with tumors that are estrogen-receptor-positive but HER2-negative--has been tearing it up in the marketplace. In Q3, Ibrance netted $230 million in sales, burying the $195 million analysts expected. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.